Effects Of Glp-1 On Glucose Homeostasis

GLP-1是一种由肠道内分泌细胞产生的肽，经肠外给药可使2型糖尿病患者的血糖正常。其作用方式是通过特定的g蛋白偶联受体增加胰腺β细胞中的cAMP。在2002年之前，没有对慢性GLP-1输注进行长期研究。我们与温哥华总医院的Grady Meneilly博士和马萨诸塞州总医院的Dariush Elahi博士合作，通过Mini Med泵持续皮下输注GLP-1，进行了为期3个月的研究。数据显示，治疗后无快速反应，糖化血红蛋白维持在7%。这些数据证实，正在开发的治疗2型糖尿病的化合物，其作用机制是通过激活GLP-1受体，是值得开发的

GLP-1, a peptide produced by the enteroendocrine cells of the gut, can normalize blood glucose in type 2 diabetes, when given parenterally. Its mode of action is by increasing cAMP in beta cells of the pancreas through a specific G-protein coupled receptor. Prior to 2002 no long-term studies with chronic GLP-1 infusions had been performed. In collaboration with Dr. Grady Meneilly, Vancouver General Hospital, and Dr. Dariush Elahi, Massachusetts General Hospital, we performed a 3-month study whereby we infused GLP-1 continuously subcutaneously via Mini Med pump. Data showed no tachyphylaxis to the treatment and it maintained a glycated hemoglobin of 7%. This data provides confirmation that compounds under development for type 2 diabetes, whose mechanism of action is via activation of the GLP-1 receptor, are worth developing We are now presently investigating the actions of a metabolic of GLP-1, the 9-36 amide fragment. In vivo, after eating, the fragment accumulates in the plasma; hence we are undertaking a study to ascertain if it per se has biological properties.